# Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia

> **NCT02034227** · PHASE1,PHASE2 · TERMINATED · sponsor: **Spirogen** · enrollment: 6 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** SG2000

## Key facts

- **NCT ID:** NCT02034227
- **Lead sponsor:** Spirogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-04
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2015-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02034227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02034227, "Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02034227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*